Please login to the form below
ASH 2019
This page shows the latest ASH 2019 news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
In the phase 3 CARDINAL study reported at the ASH congress this week, sutimlimab given as an intravenous infusion on day zero and day seven – followed by biweekly dosing – achieved the ... 11th December 2019.
Latest news
-
BMS’ oral maintenance therapy boosts survival in AML patients
During a presentation of the results at the annual ASH 2019 conference, Andrew Wei, from the Alfred Hospital and Monash University, Melbourne, Australia, said: “ Based on the results of the QUAZAR ... 11th December 2019.
-
J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data
Regeneron also presented data for its candidate in multiple myeloma at ASH, which demonstrated a 75% response rate in the higher dosed group. ... 10th December 2019.
-
Regeneron reveals first data for bispecific antibody in multiple myeloma
The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were presented at ASH 2019. ... 10th December 2019.
-
Sangamo steps up BioMarin chase with haemophilia gene therapy data
Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... ASH 2019 congress suggest Pfizer-partnered SB-525 could gain ground.
-
AstraZeneca’s Calquence impresses in previously untreated CLL
The impressive data – presented at ASH 2019 – showed that Calquence (acalabrutinib) combined with Roche’s Gazyva(obinutuzumab) significantly improved progression-free survival (PFS) when compared to standard chemo-immunotherapy treatment.
BMS’ oral maintenance therapy boosts survival in AML patients
J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data
Regeneron reveals first data for bispecific antibody in multiple myeloma
Sangamo steps up BioMarin chase with haemophilia gene therapy data
AstraZeneca’s Calquence impresses in previously untreated CLL
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
No results were found
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
